Short interest in Vertex Pharmaceuticals jumped 27.5% in May, hitting 4.82 million shares—just under 2% of the float. This ...

Stakeholders agree that the regulatory overhaul sends a strong signal to both local and international investors, positioning ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One stock that divides many investors at this time is Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG). Early on, the company built up ...

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Trillion-dollar market valuations remain a rare milestone, typically only achieved through extraordinary corporate success ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The reason is the invalidation of the breakout above the declining resistance line based on the March and late-April highs.

Vertex Pharmaceuticals, a biotech giant best known for its cystic fibrosis drugs, took a stumble after missing Q1 2025 ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.